Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).

Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression / D.Festi;F.Lodato;G.Mazzella;A.Colecchia. - STAMPA. - (2008), pp. 215-236.

Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression

FESTI, DAVIDE;LODATO, FRANCESCA;MAZZELLA, GIUSEPPE;COLECCHIA, ANTONIO
2008

Abstract

Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).
2008
Hepatitis C Virus Disease. Immunobiology and Clinical Applications
215
236
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression / D.Festi;F.Lodato;G.Mazzella;A.Colecchia. - STAMPA. - (2008), pp. 215-236.
D.Festi;F.Lodato;G.Mazzella;A.Colecchia
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/58323
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact